TY - JOUR
T1 - Molecular biomarkers in gastric cancer
AU - Elimova, Elena
AU - Wadhwa, Roopma
AU - Shiozaki, Hironori
AU - Sudo, Kazuki
AU - Estrella, Jeannelyn S.
AU - Badgwell, Brian D.
AU - Das, Prajnan
AU - Matamoros, Aurelio
AU - Song, Shumei
AU - Ajani, Jaffer A.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Gastric cancer (GC) represents a serious health problem on a global scale. Despite some recent advances in the field, the prognosis in metastatic GC remains poor. Even in localized disease the adjunctive therapies improve overall survival (OS) by only approximately 10%. A better understanding of molecular biology, which would lead to improved treatment options, is needed and is the basis for this review. Many potential biomarkers of prognostic significance have been identified, including ALDH, SHH, Sox9, HER2, EGFR, VEGF, Hippo/YAP, and MET. However, inhibition of only HER2 protein has led to a modest survival benefit. A new approach to GC treatment, which is a disease influenced by inflammation, is the exploitation of the immune system to fight disease. Two interesting targets/prognostic markers that bear further investigation in GC are PD1 and PDL, particularly given their success in the treatment of other inflammation/immune-associated malignancies.
AB - Gastric cancer (GC) represents a serious health problem on a global scale. Despite some recent advances in the field, the prognosis in metastatic GC remains poor. Even in localized disease the adjunctive therapies improve overall survival (OS) by only approximately 10%. A better understanding of molecular biology, which would lead to improved treatment options, is needed and is the basis for this review. Many potential biomarkers of prognostic significance have been identified, including ALDH, SHH, Sox9, HER2, EGFR, VEGF, Hippo/YAP, and MET. However, inhibition of only HER2 protein has led to a modest survival benefit. A new approach to GC treatment, which is a disease influenced by inflammation, is the exploitation of the immune system to fight disease. Two interesting targets/prognostic markers that bear further investigation in GC are PD1 and PDL, particularly given their success in the treatment of other inflammation/immune-associated malignancies.
UR - http://www.scopus.com/inward/record.url?scp=84999587873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84999587873&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2015.0064
DO - 10.6004/jnccn.2015.0064
M3 - Review article
C2 - 26052595
AN - SCOPUS:84999587873
SN - 1540-1405
VL - 13
SP - e19-e29
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 4
ER -